Neurvati Neurosciences and GRIN Therapeutics Welcome Dr. Gail Farfel to Their Boards
Neurvati Neurosciences and GRIN Therapeutics have recently made headlines with the appointment of Dr. Gail M. Farfel, PhD to their boards of directors. This strategic move comes at a crucial time as both companies seek to advance their development programs and capitalize on recent funding initiatives. Dr. Farfel brings over 30 years of experience in leading neuroscience research, which could prove invaluable as the companies prepare to launch a pivotal Phase 3 trial for radiprodil, aimed at treating GRIN-related neurodevelopmental disorders.
Deborah Dunsire, MD, Chairwoman of the boards, expressed her enthusiasm, stating, "We are honored to welcome Dr. Farfel... Her insights and guidance will be critical assets to our team as we plan for new levels of momentum in our development programs." This endorsement underscores the importance of Dr. Farfel’s track record and her extensive network within the life sciences industry.
A former Chief Executive Officer of ProMIS Neurosciences, Dr. Farfel is not only a neuroscientist but has also held significant roles in leading biotech firms including Zogenix and Marinus Pharmaceuticals. With over 50 scientific publications in neuropsychopharmacology, her appointment reinforces the companies' commitment to robust scientific leadership.
The timing of Dr. Farfel’s appointment aligns with Neurvati’s recent Series D financing, alongside their licensing agreement with Angelini Pharma. These developments mark a significant leap forward for both Neurvati and GRIN Therapeutics as they enhance their capabilities and broaden their market presence. As they embark on their global pivotal Phase 3 trial, the presence of an accomplished professional like Dr. Farfel could notably impact their operational path.
"I am very much looking forward to working with the team at Neurvati Neurosciences and GRIN Therapeutics as they continue to build a thoughtful, flexible model for advancing innovative neuroscience programs," Dr. Farfel stated. Her vision to harness the potential of radiprodil and other investigational therapies signifies her dedication to creating effective treatment options for patients facing neurodevelopmental disorders.
Neurvati Neurosciences, part of Blackstone Life Sciences, aims to pioneer high-potential drugs across the neuroscience landscape. Their collaborative model encourages innovative treatment options, an approach that is becoming increasingly vital in fields like psychiatry and neurology. Meanwhile, GRIN Therapeutics focuses specifically on pediatric neurodevelopmental disorders, working diligently to bring hope to families and caregivers affected by these challenges.
The joint efforts between Neurvati and GRIN Therapeutics, combined with the depth of experience that Dr. Farfel provides, set the stage for impactful developments within neuroscience therapy. Both organizations look forward to paving the way toward creating pioneering treatments that address significant unmet medical needs.
For more information about Neurvati Neurosciences, prospective readers can visit www.neurvati.com to learn more about their current initiatives and upcoming clinical trials.
Likewise, GRIN Therapeutics, which has recently entered the pivotal trial phase for radiprodil, offers insights into their groundbreaking work for treating GRIN-related NDDs through their website at www.grintherapeutics.com. With Dr. Farfel onboard, the future looks promising for both the companies and the patients they aim to serve.
Deborah Dunsire, MD, Chairwoman of the boards, expressed her enthusiasm, stating, "We are honored to welcome Dr. Farfel... Her insights and guidance will be critical assets to our team as we plan for new levels of momentum in our development programs." This endorsement underscores the importance of Dr. Farfel’s track record and her extensive network within the life sciences industry.
A former Chief Executive Officer of ProMIS Neurosciences, Dr. Farfel is not only a neuroscientist but has also held significant roles in leading biotech firms including Zogenix and Marinus Pharmaceuticals. With over 50 scientific publications in neuropsychopharmacology, her appointment reinforces the companies' commitment to robust scientific leadership.
The timing of Dr. Farfel’s appointment aligns with Neurvati’s recent Series D financing, alongside their licensing agreement with Angelini Pharma. These developments mark a significant leap forward for both Neurvati and GRIN Therapeutics as they enhance their capabilities and broaden their market presence. As they embark on their global pivotal Phase 3 trial, the presence of an accomplished professional like Dr. Farfel could notably impact their operational path.
"I am very much looking forward to working with the team at Neurvati Neurosciences and GRIN Therapeutics as they continue to build a thoughtful, flexible model for advancing innovative neuroscience programs," Dr. Farfel stated. Her vision to harness the potential of radiprodil and other investigational therapies signifies her dedication to creating effective treatment options for patients facing neurodevelopmental disorders.
Neurvati Neurosciences, part of Blackstone Life Sciences, aims to pioneer high-potential drugs across the neuroscience landscape. Their collaborative model encourages innovative treatment options, an approach that is becoming increasingly vital in fields like psychiatry and neurology. Meanwhile, GRIN Therapeutics focuses specifically on pediatric neurodevelopmental disorders, working diligently to bring hope to families and caregivers affected by these challenges.
The joint efforts between Neurvati and GRIN Therapeutics, combined with the depth of experience that Dr. Farfel provides, set the stage for impactful developments within neuroscience therapy. Both organizations look forward to paving the way toward creating pioneering treatments that address significant unmet medical needs.
For more information about Neurvati Neurosciences, prospective readers can visit www.neurvati.com to learn more about their current initiatives and upcoming clinical trials.
Likewise, GRIN Therapeutics, which has recently entered the pivotal trial phase for radiprodil, offers insights into their groundbreaking work for treating GRIN-related NDDs through their website at www.grintherapeutics.com. With Dr. Farfel onboard, the future looks promising for both the companies and the patients they aim to serve.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.